Home/Filings/4/0001104659-23-063263
4//SEC Filing

Kim Bobae 4

Accession 0001104659-23-063263

CIK 0001600132other

Filed

May 21, 8:00 PM ET

Accepted

May 22, 6:51 PM ET

Size

12.6 KB

Accession

0001104659-23-063263

Insider Transaction Report

Form 4
Period: 2023-05-18
Kim Bobae
VP Reg. Affairs & Quality
Transactions
  • Exercise/Conversion

    Common Stock

    2023-05-18$7.35/sh+266$1,9551,723 total
  • Exercise/Conversion

    Common Stock

    2023-05-18$7.50/sh+1,022$7,6651,723 total
  • Sale

    Common Stock

    2023-05-18$10.00/sh9,455$94,5501,723 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2023-05-182660 total
    Exercise: $7.35Exp: 2026-12-07Common Stock (266 underlying)
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2023-05-181,022144 total
    Exercise: $7.50Exp: 2029-09-26Common Stock (1,022 underlying)
Footnotes (3)
  • [F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.26, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  • [F2]The shares subject to this option are fully vested and exercisable.
  • [F3]This option was granted on September 26, 2019. This option vests in quarterly installments over a four-year period from the date of grant.

Issuer

Bellerophon Therapeutics, Inc.

CIK 0001600132

Entity typeother

Related Parties

1
  • filerCIK 0001959158

Filing Metadata

Form type
4
Filed
May 21, 8:00 PM ET
Accepted
May 22, 6:51 PM ET
Size
12.6 KB